Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

Company Overview

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Key Stats

• Today's Range: $7.48 to $7.78
• 50-Day Range: $7.20 to $8.67
• 52-Week Range: $4.71 to $10.67
• Volume: 1.18 million shs
• Average Volume: 1.35 million shs
• Market Capitalization: $1.06 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Buy

Aurinia Pharmaceuticals Stock Analysis - MarketRank™

Aurinia Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat, and ranked 498th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Aurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aurinia Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 409.09%

Earnings Growth

Earnings for Aurinia Pharmaceuticals are expected to grow by 409.09% in the coming year, from $0.11 to $0.56 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aurinia Pharmaceuticals is -51.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aurinia Pharmaceuticals is -51.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aurinia Pharmaceuticals has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.41% of the float of Aurinia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Aurinia Pharmaceuticals has recently increased by 0.44%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aurinia Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Aurinia Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.41% of the float of Aurinia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Aurinia Pharmaceuticals has recently increased by 0.44%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 1.71

News Sentiment

Aurinia Pharmaceuticals has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

Only 16 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.

MarketBeat Follows

5 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Aurinia Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,753,094.00 in company stock.

Percentage Held by Insiders

Only 4.30% of the stock of Aurinia Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.

AUPH Stock Analysis - Frequently Asked Questions

How have AUPH shares performed this year?

Aurinia Pharmaceuticals' stock was trading at $8.98 at the beginning of 2025. Since then, AUPH stock has decreased by 13.9% and is now trading at $7.73.
View the best growth stocks for 2025 here.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) released its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. The business's quarterly revenue was up 37.6% on a year-over-year basis.
Read the conference call transcript.

Who are Aurinia Pharmaceuticals' major shareholders?

Top institutional investors of Aurinia Pharmaceuticals include GAMMA Investing LLC (0.03%). Insiders that own company stock include Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Stephen P Robertson, Greg Keenan, George M Milne Jr, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan.
View institutional ownership trends.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

• Last Earnings: 8/01/2024
• Today: 4/15/2025
• Next Earnings (Estimated): 5/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AUPH
• CIK: 1600620
• Web: www.auriniapharma.com
• Phone: 250-708-4272
• Fax: 250-744-2498
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.50
• High Stock Price Target: $13.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +48.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.05
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 70.27
• P/E Growth: N/A
• Net Income: $-78,020,000.00
• Net Margins: -10.23%
• Pretax Margin: -9.14%
• Return on Equity: -4.41%
• Return on Assets: -3.07%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 5.60
• Quick Ratio: 5.11

Sales & Book Value

• Annual Sales: $235.13 million
• Price / Sales: 4.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.63 per share
• Price / Book: 2.94

Miscellaneous

• Outstanding Shares: 137,339,000
• Free Float: 137,022,000
• Market Cap: $1.06 billion
• Optionable: Optionable
• Beta: 1.20